Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-08-11FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2017-08-11FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET XR (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals.
-
CLINICAL_TRIALS trial_result · 2017-08-11Clinical Trial Update: Diabetes Scorecard Educational Intervention Study [NA]
A completed clinical trial evaluating a diabetes scorecard educational intervention for adults with Type 2 diabetes.
-
FDA approval · 2017-08-10FDA Approved: TRADJENTA — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for Tradjenta (linagliptin) filed by Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA approval · 2017-08-10FDA Approved: JENTADUETO — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO (linagliptin and metformin hydrochloride) by Boehringer Ingelheim Pharmaceuticals…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2017-08-10FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride) from Boehringer Ingelheim Pharmaceut…
-
FDA approval · 2017-08-10FDA Approved: JANUVIA — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for JANUVIA (sitagliptin) submitted by Merck Sharp & Dohme LLC.
-
FDA approval · 2017-08-10FDA Approved: JANUMET — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET (sitagliptin and metformin hydrochloride) from Merck Sharp & Dohme LLC. The notice confi…
-
FDA approval · 2017-08-10FDA Approved: JANUMET XR — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for JANUMET XR (sitagliptin and metformin hydrochloride XR) from Merck Sharp & Dohme LLC.
-
FDA approval · 2017-08-10FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) from Boehringer Ingelheim Pharmaceuticals, Inc., repres…
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: Use of Sitagliptin to Decrease Microalbuminuria [Phase 4]
Phase 4 clinical trial evaluating sitagliptin for reducing microalbuminuria in patients with type 2 diabetes; the study was terminated and r…
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients
The study reported a completed trial evaluating whether better glucose control in type 2 diabetes affects the response to aspirin.
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones
This clinical trial update reports on the endocrine effects of a duodenal-jejunal bypass sleeve on type 2 diabetes mellitus and obesity. It …
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: New IR Biomarkers (Myokines) in Colombian People
Completed clinical trial from the University of Los Andes in Colombia evaluating new insulin resistance biomarkers (myokines) in Colombian p…
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study [Phase 4]
This is a Phase 4 clinical trial comparing basal-bolus insulin therapy to standard inpatient therapy for Type 2 Diabetes Mellitus. The curre…
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers [Phase 1]
This update notes the completion of a Phase 1 pharmacokinetic study of CKD-395 (0.25/500 mg) in healthy male volunteers.
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1) [Phase 1]
Chong Kun Dang Pharmaceutical completed a Phase 1 drug-drug interaction study of CKD-396 in patients with type 2 diabetes mellitus. The tria…
-
CLINICAL_TRIALS research · 2017-08-08Clinical Trial Update: The Association Between Food Insecurity and Incident Type 2 Diabetes in Canada: A Population-based Cohort Study
A completed population-based cohort study examining the association between food insecurity and incident Type 2 diabetes in Canada.
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: Korean Post-marketing Surveillance for Kombiglyze XR®
Completed results of a Korean post-marketing surveillance study of Kombiglyze XR (saxagliptin/metformin) in adults with Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus [Phase 4]
Phase 4 trial evaluating whether the SLC30A8 rs13266634 genetic variant alters the glycemic response to zinc supplementation in Egyptian pat…
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: The Fructose and Allulose Catalytic Effects (FACE) Trial [NA]
The FACE trial, sponsored by the University of Toronto, investigating the catalytic effects of fructose and allulose in Type 2 Diabetes, has…
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: Korean Post-marketing Surveillance for Onglyza®
Completed Korean post-marketing surveillance study evaluating Onglyza (saxagliptin) for type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2017-08-07Clinical Trial Update: A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin [Phase 2]
Pfizer reports results from a 12-week Phase 2 trial evaluating PF-06291874 once daily in adults with type 2 diabetes mellitus inadequately c…
-
CLINICAL_TRIALS trial_result · 2017-08-07Clinical Trial Update: Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs [Phase 1]
Phase 1 clinical trial evaluating weight loss and body composition changes after dosing with placebo or two active drugs in adults with Type…
-
CLINICAL_TRIALS trial_result · 2017-08-04Clinical Trial Update: Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate [Phase 1]
Phase 1 clinical trial update evaluating Rosiglitazone Maleate in people with type 2 diabetes mellitus to assess the utility of novel techno…